MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia
MetadataShow full item record
CitationTagde, Ashujit, Hasan Rajabi, Dina Stroopinsky, Reddy Gali, Maroof Alam, Audrey Bouillez, Surender Kharbanda, Richard Stone, David Avigan, and Donald Kufe. 2016. “MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia.” Oncotarget 7 (26): 38974-38987. doi:10.18632/oncotarget.9777. http://dx.doi.org/10.18632/oncotarget.9777.
AbstractAberrant DNA methylation is a hallmark of acute myeloid leukemia (AML); however, the regulation of DNA methyltransferase 1 (DNMT1), which is responsible for maintenance of DNA methylation patterns, has largely remained elusive. MUC1-C is a transmembrane oncoprotein that is aberrantly expressed in AML stem-like cells. The present studies demonstrate that targeting MUC1-C with silencing or a pharmacologic inhibitor GO-203 suppresses DNMT1 expression. In addition, MUC1 expression positively correlates with that of DNMT1 in primary AML cells, particularly the CD34+/CD38− population. The mechanistic basis for this relationship is supported by the demonstration that MUC1-C activates the NF-κB p65 pathway, promotes occupancy of the MUC1-C/NF-κB complex on the DNMT1 promoter and drives DNMT1 transcription. We also show that targeting MUC1-C substantially reduces gene promoter-specific DNA methylation, and derepresses expression of tumor suppressor genes, including CDH1, PTEN and BRCA1. In support of these results, we demonstrate that combining GO-203 with the DNMT1 inhibitor decitabine is highly effective in reducing DNMT1 levels and decreasing AML cell survival. These findings indicate that (i) MUC1-C is an attractive target for the epigentic reprogramming of AML cells, and (ii) targeting MUC1-C in combination with decitabine is a potentially effective clinical approach for the treatment of AML.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:29739046
- HMS Scholarly Articles